The global Opioid-Induced Constipation market was valued at 219.65 Million USD in 2020 and will grow with a CAGR of 5% from 2020 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation.Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%. North America is the largest Sales place, with a Sales market share nearly 56.48% in 2017. Following North America, Europe is the second largest Sales place with the Sales market share of 20.49%.
By Market Verdors:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
By Types:
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
By Applications:
Hospital
Pharmacy
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market's competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Opioid-Induced Constipation Market Size Analysis from 2022 to 2027
1.5.1 Global Opioid-Induced Constipation Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Opioid-Induced Constipation Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Opioid-Induced Constipation Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Opioid-Induced Constipation Industry Impact
Chapter 2 Global Opioid-Induced Constipation Competition by Types, Applications, and Top Regions and Countries
2.1 Global Opioid-Induced Constipation (Volume and Value) by Type
2.1.1 Global Opioid-Induced Constipation Consumption and Market Share by Type (2016-2021)
2.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2016-2021)
2.2 Global Opioid-Induced Constipation (Volume and Value) by Application
2.2.1 Global Opioid-Induced Constipation Consumption and Market Share by Application (2016-2021)
2.2.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2016-2021)
2.3 Global Opioid-Induced Constipation (Volume and Value) by Regions
2.3.1 Global Opioid-Induced Constipation Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Opioid-Induced Constipation Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Opioid-Induced Constipation Consumption by Regions (2016-2021)
4.2 North America Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
4.10 South America Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Opioid-Induced Constipation Market Analysis
5.1 North America Opioid-Induced Constipation Consumption and Value Analysis
5.1.1 North America Opioid-Induced Constipation Market Under COVID-19
5.2 North America Opioid-Induced Constipation Consumption Volume by Types
5.3 North America Opioid-Induced Constipation Consumption Structure by Application
5.4 North America Opioid-Induced Constipation Consumption by Top Countries
5.4.1 United States Opioid-Induced Constipation Consumption Volume from 2016 to 2021
5.4.2 Canada Opioid-Induced Constipation Consumption Volume from 2016 to 2021
5.4.3 Mexico Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 6 East Asia Opioid-Induced Constipation Market Analysis
6.1 East Asia Opioid-Induced Constipation Consumption and Value Analysis
6.1.1 East Asia Opioid-Induced Constipation Market Under COVID-19
6.2 East Asia Opioid-Induced Constipation Consumption Volume by Types
6.3 East Asia Opioid-Induced Constipation Consumption Structure by Application
6.4 East Asia Opioid-Induced Constipation Consumption by Top Countries
6.4.1 China Opioid-Induced Constipation Consumption Volume from 2016 to 2021
6.4.2 Japan Opioid-Induced Constipation Consumption Volume from 2016 to 2021
6.4.3 South Korea Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 7 Europe Opioid-Induced Constipation Market Analysis
7.1 Europe Opioid-Induced Constipation Consumption and Value Analysis
7.1.1 Europe Opioid-Induced Constipation Market Under COVID-19
7.2 Europe Opioid-Induced Constipation Consumption Volume by Types
7.3 Europe Opioid-Induced Constipation Consumption Structure by Application
7.4 Europe Opioid-Induced Constipation Consumption by Top Countries
7.4.1 Germany Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.2 UK Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.3 France Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.4 Italy Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.5 Russia Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.6 Spain Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.7 Netherlands Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.8 Switzerland Opioid-Induced Constipation Consumption Volume from 2016 to 2021
7.4.9 Poland Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 8 South Asia Opioid-Induced Constipation Market Analysis
8.1 South Asia Opioid-Induced Constipation Consumption and Value Analysis
8.1.1 South Asia Opioid-Induced Constipation Market Under COVID-19
8.2 South Asia Opioid-Induced Constipation Consumption Volume by Types
8.3 South Asia Opioid-Induced Constipation Consumption Structure by Application
8.4 South Asia Opioid-Induced Constipation Consumption by Top Countries
8.4.1 India Opioid-Induced Constipation Consumption Volume from 2016 to 2021
8.4.2 Pakistan Opioid-Induced Constipation Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Opioid-Induced Constipation Market Analysis
9.1 Southeast Asia Opioid-Induced Constipation Consumption and Value Analysis
9.1.1 Southeast Asia Opioid-Induced Constipation Market Under COVID-19
9.2 Southeast Asia Opioid-Induced Constipation Consumption Volume by Types
9.3 Southeast Asia Opioid-Induced Constipation Consumption Structure by Application
9.4 Southeast Asia Opioid-Induced Constipation Consumption by Top Countries
9.4.1 Indonesia Opioid-Induced Constipation Consumption Volume from 2016 to 2021
9.4.2 Thailand Opioid-Induced Constipation Consumption Volume from 2016 to 2021
9.4.3 Singapore Opioid-Induced Constipation Consumption Volume from 2016 to 2021
9.4.4 Malaysia Opioid-Induced Constipation Consumption Volume from 2016 to 2021
9.4.5 Philippines Opioid-Induced Constipation Consumption Volume from 2016 to 2021
9.4.6 Vietnam Opioid-Induced Constipation Consumption Volume from 2016 to 2021
9.4.7 Myanmar Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 10 Middle East Opioid-Induced Constipation Market Analysis
10.1 Middle East Opioid-Induced Constipation Consumption and Value Analysis
10.1.1 Middle East Opioid-Induced Constipation Market Under COVID-19
10.2 Middle East Opioid-Induced Constipation Consumption Volume by Types
10.3 Middle East Opioid-Induced Constipation Consumption Structure by Application
10.4 Middle East Opioid-Induced Constipation Consumption by Top Countries
10.4.1 Turkey Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.3 Iran Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.5 Israel Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.6 Iraq Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.7 Qatar Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.8 Kuwait Opioid-Induced Constipation Consumption Volume from 2016 to 2021
10.4.9 Oman Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 11 Africa Opioid-Induced Constipation Market Analysis
11.1 Africa Opioid-Induced Constipation Consumption and Value Analysis
11.1.1 Africa Opioid-Induced Constipation Market Under COVID-19
11.2 Africa Opioid-Induced Constipation Consumption Volume by Types
11.3 Africa Opioid-Induced Constipation Consumption Structure by Application
11.4 Africa Opioid-Induced Constipation Consumption by Top Countries
11.4.1 Nigeria Opioid-Induced Constipation Consumption Volume from 2016 to 2021
11.4.2 South Africa Opioid-Induced Constipation Consumption Volume from 2016 to 2021
11.4.3 Egypt Opioid-Induced Constipation Consumption Volume from 2016 to 2021
11.4.4 Algeria Opioid-Induced Constipation Consumption Volume from 2016 to 2021
11.4.5 Morocco Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 12 Oceania Opioid-Induced Constipation Market Analysis
12.1 Oceania Opioid-Induced Constipation Consumption and Value Analysis
12.2 Oceania Opioid-Induced Constipation Consumption Volume by Types
12.3 Oceania Opioid-Induced Constipation Consumption Structure by Application
12.4 Oceania Opioid-Induced Constipation Consumption by Top Countries
12.4.1 Australia Opioid-Induced Constipation Consumption Volume from 2016 to 2021
12.4.2 New Zealand Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 13 South America Opioid-Induced Constipation Market Analysis
13.1 South America Opioid-Induced Constipation Consumption and Value Analysis
13.1.1 South America Opioid-Induced Constipation Market Under COVID-19
13.2 South America Opioid-Induced Constipation Consumption Volume by Types
13.3 South America Opioid-Induced Constipation Consumption Structure by Application
13.4 South America Opioid-Induced Constipation Consumption Volume by Major Countries
13.4.1 Brazil Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.2 Argentina Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.3 Columbia Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.4 Chile Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.5 Venezuela Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.6 Peru Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Opioid-Induced Constipation Consumption Volume from 2016 to 2021
13.4.8 Ecuador Opioid-Induced Constipation Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Opioid-Induced Constipation Business
14.1 Takeda Pharmaceuticals
14.1.1 Takeda Pharmaceuticals Company Profile
14.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Specification
14.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Bayer
14.2.1 Bayer Company Profile
14.2.2 Bayer Opioid-Induced Constipation Product Specification
14.2.3 Bayer Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Sanofi
14.3.1 Sanofi Company Profile
14.3.2 Sanofi Opioid-Induced Constipation Product Specification
14.3.3 Sanofi Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Mallinckrodt
14.4.1 Mallinckrodt Company Profile
14.4.2 Mallinckrodt Opioid-Induced Constipation Product Specification
14.4.3 Mallinckrodt Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Salix (Bausch Health)
14.5.1 Salix (Bausch Health) Company Profile
14.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Specification
14.5.3 Salix (Bausch Health) Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 AstraZeneca
14.6.1 AstraZeneca Company Profile
14.6.2 AstraZeneca Opioid-Induced Constipation Product Specification
14.6.3 AstraZeneca Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Progenics Pharmaceuticals
14.7.1 Progenics Pharmaceuticals Company Profile
14.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Specification
14.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Purdue Pharm
14.8.1 Purdue Pharm Company Profile
14.8.2 Purdue Pharm Opioid-Induced Constipation Product Specification
14.8.3 Purdue Pharm Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 Nektar Therapeutics
14.9.1 Nektar Therapeutics Company Profile
14.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Specification
14.9.3 Nektar Therapeutics Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 Daiichi Sankyo
14.10.1 Daiichi Sankyo Company Profile
14.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Specification
14.10.3 Daiichi Sankyo Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 Prestige
14.11.1 Prestige Company Profile
14.11.2 Prestige Opioid-Induced Constipation Product Specification
14.11.3 Prestige Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 GSK
14.12.1 GSK Company Profile
14.12.2 GSK Opioid-Induced Constipation Product Specification
14.12.3 GSK Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Shionogi
14.13.1 Shionogi Company Profile
14.13.2 Shionogi Opioid-Induced Constipation Product Specification
14.13.3 Shionogi Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Opioid-Induced Constipation Market Forecast (2022-2027)
15.1 Global Opioid-Induced Constipation Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Opioid-Induced Constipation Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Opioid-Induced Constipation Value and Growth Rate Forecast (2022-2027)
15.2 Global Opioid-Induced Constipation Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Opioid-Induced Constipation Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Opioid-Induced Constipation Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Opioid-Induced Constipation Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Opioid-Induced Constipation Consumption Forecast by Type (2022-2027)
15.3.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2022-2027)
15.3.3 Global Opioid-Induced Constipation Price Forecast by Type (2022-2027)
15.4 Global Opioid-Induced Constipation Consumption Volume Forecast by Application (2022-2027)
15.5 Opioid-Induced Constipation Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
Request Sample 
Request Discount 
Inquire Before Buy
